Category: Cosmetic/AestheticSyndicate content

Medical device manufacturers making cosmetic / aesthetic products.

Ulthera pulls $86M IPO in favor of $600M merger

July 23, 2014 by Arezu Sarvestani

Aesthetics devices maker Ulthera withdraws its $86 million initial public offering after agreeing to an acquisition by Merz that's valued at up to $600 million.

Ulthera pulls IPO in favor of merger

Arizona device maker Ulthera is ditching its planned initial public offering in favor of a $600 million merger with larger aesthetics company Merz Inc., according to an SEC filing.

Allergan cuts 1,500 jobs, faces SEC complaint

July 21, 2014 by Arezu Sarvestani

Botox-maker Allergan announces restructuring measures that will cut 13% of its global workforce as the company sinks deeper into a months-long battle against activist investors and attempts at a takeover.

Updated July 21, 2014, at 12:40 p.m. EST with additional information on Allergan's earnings.

A countdown to failure for Valeant's hostile $53B Allergan takeover

July 18, 2014 by Arezu Sarvestani

Activist investor Bill Ackman urges shareholders to take action before time runs out on Valeant Pharmaceuticals' hostile $53 billion bid to acquire Allergan.

A countdown to failure for Valeant's hostile $53B Allergan takeover

Report: Another activist investor pressures Allergan to sell

June 27, 2014 by Arezu Sarvestani

Another hedge fund buys a massive stake in Botox-maker Allergan, throwing its support behind Valeant Pharmaceuticals' unrequited acquisition bid, according to a report.

Report: Another activist investor pressures Allergan to sell

Another player entered the arena in the running saga over Allergan (NYSE:AGN) as hedge fund Paulson & Co bought up a huge chunk of the Botox-maker's shares, according to Reuters.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Valeant goes hostile in bid for Allergan

June 18, 2014 by Arezu Sarvestani

Valeant Pharmaceuticals makes its promised hostile play in a $53 billion attempt to take over Botox-maker Allergan.

Valeant goes hostile in bid for Allergan

Valeant Pharmaceuticals is preparing to officially launch its long-promised hostile takeover bid for Allergan (NYSE:AGN), aiming to solicit support from Allergan shareholders to host a special meeting outside of the company's control.

Ackman takes Allergan to court to defend against 'poison pill'

June 13, 2014 by Arezu Sarvestani

Activist investor William Ackman takes Allergan to court to ensure that the company won't activate its "poison pill" over a shareholder meeting that Valeant Pharmaceuticals hopes will help its unrequited acquisition efforts.

Ackman takes Allergan to court to defend against 'poison pill'

Activist investor William Ackman is looking to take Allergan (NYSE:AGN) to court to ensure that the company won't activate it's "poison pill" when prospective acquirer Valeant Pharmaceuticals holds its shareholder meeting.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Allergan board members unanimously reject Valeant's $53B offer

June 10, 2014 by Arezu Sarvestani

Every member of Allergan's board of directors votes to turn down Valeant Pharmaceuticals' unsolicited $53.3 billion acquisition offer.

Allergan board members unanimously reject Valeant's $53B offer

Aesthetic devices giant Allergan (NYSE:AGN) roundly rejected the latest unsolicited acquisition offer from Valeant Pharmaceuticals and activist investor William Ackman, saying the increased $53.3 billion bid still undervalues the company.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp